FREE Account Opening + No Clearing Fees
Loading...
November 3, 2022 - November 7, 2022

Global Health IPO Review & Recommendations

BP Equities (BP Wealth), Choice Equity Broking Pvt Ltd, Dilip Davda, Nirmal Bang and Reliance Securities have given "Apply" recommendation to Global Health IPO. Canara Bank, Capital Market, Jainam Broking limited and InvestorGain.com have given "May Apply" recommendation to Global Health IPO. Axis Capital, HDFC Securities Limited and Sharekhan Limited have "Not Rated" the IPO.

Global Health IPO Review Summary from brokers and analysts

Review By Apply May Apply Neutral Avoid Not Rated
Count 5 4 0 0 3
% 41.67 33.33 0.00 0.00 25.00

Global Health IPO Analysis By Brokers/Analysts

Reviewer Recommendation Past Reviews
Axis CapitalExternal link Not Rated
BP Equities (BP Wealth)External link Apply
Canara BankExternal link May Apply
Capital MarketExternal link May Apply
Choice Equity Broking Pvt LtdExternal link Apply
Dilip Davda Apply
HDFC Securities LimitedExternal link Not Rated
Jainam Broking limitedExternal link May Apply
Nirmal BangExternal link Apply
Reliance SecuritiesExternal link Apply
Sharekhan LimitedExternal link Not Rated
InvestorGain.comExternal link May Apply

Global Health IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Global Health IPO is 45. Their analysis recommends May subscribe for the IPO.

Reviewer Rating Score Rating
Capital Market 45 May subscribe

Global Health IPO Review by Dilip Davda (Apply)

[Dilip Davda]  GHL is operating under the most popular healthcare brand “Medanta” and posted growth over the years in its scale of operations. The issue is attractively priced based on its financial data and well compares with listed peers. Investors may consider an investment with medium to long-term perspectives. Read detail review...


Global Health IPO Review by Members

Global Health IPO Reviews, analysis and views by popular members. Read Global Health Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Global Health IPO Review Summary by Members

Review By Apply May Apply Neutral Avoid
Count 7 0 3 3
% 53.85 0.00 23.08 23.08
Clear Search
Member Review
Abhijeet Kumar

Avoid

Instead of applying in such poor quality IPO like Fusion and Global health its better to buy good quality scrips from secondary market which are trading at cheap valuations. Few of my suggestions to buy would be : Sanofi India, Johnson Control, Tamilnad Merchantile Bank, GE T&D India, Bector Foods, Railtel etc,

November 3, 2022 2:20:31 AM
AJS

Apply for Long Term at Upper Price Band

Available at reasonable valuations compared to Apollo, Fortis.

November 2, 2022 9:31:15 PM
arunARUN
IPO Guru IPO Guru (1800+ Posts, 1600+ Likes)

Apply for Short Term at Cut-off Price

Attractively priced. Though share is good for long term also but in short term prices may run ahead of fundamentals

October 29, 2022 9:05:21 AM
B.M.SURANA
IPO Guru IPO Guru (2500+ Posts, 4700+ Likes)

Apply for Long Term at Cut-off Price

Fundamentally strong Company.
Brand Value
World ke Top 200 Hospitals Mein ek hai "Medanta"
KhelaHobe
खेला होबे
খেলা হবে

I Like It. 1

November 3, 2022 1:04:21 PM
bansalVijay

Apply for Listing Gain at Upper Price Band

Many people are comparing it with max hospital and inferring Medanta costly but how. Max with 600 crores profit has market cap of 41000 crores while Medanta with 200 crores profit seems to have market cap of 8000 crores. Can anyone shed light on this.

October 30, 2022 10:39:44 AM
Crow
IPO Mentor IPO Mentor (700+ Posts, 900+ Likes)

Apply for Listing Gain at Cut-off Price

Barring poor GMP (12), high OFS (1700 cr), and low post-IPO promoter holding (33), I see some potential in this hospital stock. Hospitals have been usually well-received by the markets, plus the decent subscription levels tell me this may be a good bet even for longterm. Taking the gamble. 5 red flags out of 13.

November 7, 2022 1:49:03 PM
Liger
Top Contributor Top Contributor (300+ Posts, 500+ Likes)

Neutral

IPO pricing is at its fair value.
Good Brand.
Good for Long term.

I Like It. 1

November 2, 2022 3:59:20 PM
MAMU
IPO Guru IPO Guru (1600+ Posts, 1100+ Likes)

Neutral

In waves of MAIN BOARD & SMES ipo, this will have a tough competition.
Listing gain may be surprising.

November 3, 2022 11:34:29 PM
Nomee

Apply for Listing Gain at Upper Price Band

This is THE Brand with reasonable valuation, Must subscribe.

November 3, 2022 7:07:29 PM
ramsita (300+ Posts)

Avoid

Uncertaintey

November 3, 2022 1:51:14 PM
Stark

Avoid

HUGE OFS ISSUE. NOT FAIRLY PRICED AND POST ISSUE HOLDING WILL JUST 33%.

October 30, 2022 10:02:44 PM
Top Contributor

Neutral

May Apply

November 1, 2022 9:26:35 AM
XCapitalMarkets

Apply for Long Term at Cut-off Price

Great brand value, high-quality business, solid management. Growth path in place, and new hospitals ramping up fast. Valued at 18.5x FY22 EBITDA, whereas peers trade at average of 25x, so attractive pricing.

November 3, 2022 9:29:36 AM

Post Recommendation Manage Recommendations

Note:

  • The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
  • We reserve the right to remove any objectionable post without providing a reason.